title: Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial.
abstract: OBJECTIVE
  To evaluate the clinical and hormonal response of topically applied cyproterone acetate, oral cyproterone acetate, and placebo lotion in women with acne.
  
  
  METHODS
  Placebo-controlled, randomized study.
  
  
  METHODS
  Patients were recruited from the Institute of Endocrine Cosmetics, Vienna, Austria.
  
  
  METHODS
  Forty women with acne.
  
  
  METHODS
  Treatment with oral medication consisting of 0.035 mg of ethinyl estradiol and 2 mg of cyproterone acetate (n=12), 20 mg of topical cyproterone acetate lotion (n=12), and placebo lotion (n=16) was offered. Patients were assessed monthly for 3 months.
  
  
  METHODS
  Clinical grading according to acne severity and lesion counts as well as determinations of serum cyproterone acetate concentrations.
  
  
  RESULTS
  After 3 months of therapy with topical cyproterone acetate, the decrease of mean facial acne grade from 1.57 to 0.67 was significantly better (P<.05) compared with placebo (which showed a change from 1.57 to 1.25), but not compared with oral medication (1.56 to 0.75) (P>.05). Lesion counts also decreased from 35.9 to 9.1 in the topical cyproterone acetate group compared with oral medication (45.4 to 15.5) (P>.05) and placebo (38.2 to 23.1) (P<.05). After topical cyproterone acetate treatment, serum cyproterone acetate concentrations were 10 times lower than those found after oral cyproterone acetate intake.
  
  
  CONCLUSIONS
  The therapeutic effect of topically applied cyproterone acetate for acne treatment was clearly demonstrated. Topically applied sexual steroids in combination with liposomes are as effective as oral antiandrogen medication in acne treatment, while reducing the risk of adverse effects and avoiding high serum cyproterone acetate concentrations.
authors.affiliation: Division of Gynecological Endocrinology and Reproductive Medicine, General Hospital, University of Vienna, Wien, Austria. Doris.Gruber@akh-wien.ac.at
authors.forename: D M
authors.initials: DM
authors.lastname: Gruber
authors.forename: M O
authors.initials: MO
authors.lastname: Sator
authors.forename: E A
authors.initials: EA
authors.lastname: Joura
authors.forename: E M
authors.initials: EM
authors.lastname: Kokoschka
authors.forename: G
authors.initials: G
authors.lastname: Heinze
authors.forename: J C
authors.initials: JC
authors.lastname: Huber
mesh_terms: D000152:Acne Vulgaris / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate